Positron emission tomography (PET) is an in vivo molecular imaging tool which is widely used in nuclear medicine for early diagnosis and treatment follow-up of many brain diseases. PET uses biomolecules as probes which are labeled with radionuclides of short half-lives, synthesized prior to the imaging studies. These probes are called radiotracers. Fluorine-18 is a radionuclide routinely used in the radiolabeling of neuroreceptor ligands for PET because of its favorable half-life of 109.8 min. The delivery of such radiotracers into the brain provides images of transport, metabolic, and neurotransmission processes on the molecular level. After a short introduction into the principles of PET, this review mainly focuses on the strategy of radiotracer development bridging from basic science to biomedical application. Successful radiotracer design as described here provides molecular probes which not only are useful for imaging of human brain diseases, but also allow molecular neuroreceptor imaging studies in various small-animal models of disease, including geneticallyengineered animals. Furthermore, they provide a powerful tool for in vivo pharmacology during the process of pre-clinical drug development to identify new drug targets, to investigate pathophysiology, to discover potential drug candidates, and to evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo.
Introduction
Positron emission tomography (PET) is an in vivo molecular imaging tool widely used in nuclear medicine for early diagnosis and treatment follow-up of many brain diseases. Positron-emitting radionuclide-labeled substances allow the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems by highly sensitive coincidence-detection fusion accuracy, provides an advanced diagnostic tool and research platform [2, 3] .
PET and SPECT use biomolecules as probes, labeled with radionuclides of short half-lives, synthesized prior to the imaging studies. These probes are called radiotracers.
According to the concept developed by George von
Hevesy [4] a radiotracer is a chemical compound in which one or more atoms have been replaced by its radioisotope.
By virtue of its radioactive decay, it can be used to follow the original compound as it acts in the same manner.
Due to the extremely small concentrations required, the radiotracer does not disturb the systemic processes to be studied. This allows the tracing of chemical, biochemical, and physiological processes and investigation of their functions and capacities.
Although SPECT is the most common imaging tool in clinical nuclear medicine, this review is focused on PET.
SPECT primarily uses radioiodine, e.g. H, OH; "isosteric, isoelectronic, or bioisosteric labeling"), generate rather small affi nity changes, if any. 18 F is considered the most suitable radionuclide for PET because of its fi ve-fold longer half-life (109.8 min) than 11 C, its high β + yield (97%) and its lower positron energy maximum of 640 keV (IAEA, Nuclear Data Services, https:// www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html).
Despite the limitations, the principles and strategies for radiotracer development described below also apply to SPECT. Also, aspects of radiation safety, toxicology issues, quality control, licensing, and regulatory control, which need to be considered for the production of radiopharmaceuticals suitable for administration to humans, have been reviewed extensively elsewhere [5] . Meanwhile, a highly regulated system for radiopharmaceutical production has been established in most of the developed countries (http://ec.europa.eu/ health/documents/eudralex/vol-4/index_en.htm). This topic is therefore excluded from further consideration.
Successful radiotracer design as described below does not necessarily lead to human application. Nowadays, special PET and SPECT devices are available for smallanimal imaging, allowing molecular neuroreceptor imaging studies in various models of disease including geneticallyengineered animals [6, 7] . They provide a powerful tool for in vivo pharmacology during the process of pre-clinical drug development to identify new drug targets, to investigate pathophysiology, to discover potential drug candidates, and to evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo [8] .
The general sequence of radiotracer development is shown in Fig. 1 and can be followed up in a short video available at http://www.beilstein.tv/tvpost/toxic-epibatidinewas-structurally-modified-to-image-alzheimer%C2%B4s-disease/. This demonstrates how chemical/pharmaceutical and biochemical/pharmacological steps interact to finally decide whether to break-off or continue the development process. PET radiotracers that have been developed for neuroreceptor imaging and have already been used in humans are listed in Table 1 .
Target Selection and Identifi cation of Lead Structures
Careful selection of the target to be imaged in combination [19] Adenosine receptor: A 2A [ 11 C]TMSX Mishina et al. 2011 [20] Adenosine receptor: A 2A [¹¹C]SCH442416 Ramlackhansingh et al. 2011 [21] Cannabinoid [23] Cannabinoid receptor: CB 1 [ 11 C]OMAR Wong et al. 2010 [24] Cannabinoid receptor: CB 2 [ 11 C]NE40 Ahmad et al. 2013 [25] [52] GABA-benzodiazepine receptor: α5
Lingford-Hughes e al. 2002 [53] Opioid receptor:
Frost et al. 1990 [54] Opioid receptor:
Madar et al. 1997 [55] Opioid receptor:
Tomasi et al. 2010 [56] Opioid receptor: unselective
Frost et al. 1990 [54] Opioid A schematic view of this complex situation, identifying important molecules involved in the three classes of diseases noted above, is shown in Fig. 2 . Notably, many of them are identical though occurring in different contexts.
Therefore, it is highly likely that radiotracers designed, for instance, for imaging a certain key protein in the etiology of Alzheimer´s disease (AD) may also be of major importance for other diseases, which further justifies the efforts expended on radiotracer development.
For example, sigma 1 (σ 1 ) receptors are chaperones involved in the suppression of oxidative stress, a feature that links them to numerous brain diseases [89] . Postmortem studies have shown loss of σ 1 binding sites in the hippocampus of patients with AD [90] and in the cortex of patients with schizophrenia [91] . Overexpression of σ receptors has been found in many brain tumor cell lines and in human brain tumors [92] . The neuroprotective potential of σ 1 receptor agonists has been shown in different models of neurodegeneration [89, 93] and is expected to be important for cancerous diseases as well [92, 94] .
As another example, impaired cholinergic neurotransmission is a key feature of AD and the related cognitive impairment is at least partially associated with loss of cortical nicotinic acetylcholine receptors (nAChRs) [6, 95] .
There is evidence that both subtypes with the highest expression in the brain are involved: α4β2 and α7 nAChRs.
Accordingly, these subtypes have been chosen for radiotracer development [6, 96, 97] . However, these nAChRs are not only key proteins in neurodegenerative diseases ( Fig. 2A) but also in many other brain diseases such as drug addiction, schizophrenia (Fig. 2B) , and possibly cancer (Fig. 2C) . This offers the advantage that corresponding radiotracers may also be used to answer questions related to these diseases.
The radiotracer (S)-[ 11 C]nicotine, one of the very first positron-emitting receptor ligands, was initially developed to investigate the distribution of nicotine in vivo and later tested for PET imaging of nAChRs in the human brain [6, 98] .
However, co-administration of unlabeled nicotine failed to displace much of the radioligand, indicating that the PET signal did not sensitively reveal specifi c binding to nAChRs.
Cerebral (S)-[
11 C]nicotine uptake proved mainly to be determined by blood fl ow, rather than the local abundance of nAChRs in vivo [6] . This indicates the importance not only of target but also of lead structure identification. Clearly, 
Target Characterization and in vitro Screening of

New Compounds
High-affinity binding is one of the most important prerequisites for radiotracers targeting neuroreceptors [100, 101] . As a rule of thumb, a binding potential (BP = B max /K D ) of >2 is required for a good PET radioligand [102] . This implies the need to search for higher target affi nity (1/K D ) if the receptor density (B max ) is low. For example, the receptor densities for α7 nAChRs in the human brain are between 2 and 16 fmol/mg tissue [96] . Accordingly, a K D between 1 and 8 nmol/L is required to fulfil the minimal criteria. The best α7 nAChR PET radiotracers available so far have affi nities between 0.3 and 10 nmol/L [6] .
Other important prerequisites for PET radiotracers are target selectivity and low non-specific binding [100, 101] .
The displacement of radiotracer binding by ligands specifi c for non-target sites indicates lack of selectivity. This is a general disadvantage, because the specifi c signal obtained in neuroimaging studies is reduced (i.e. constitutes only a fraction of the total signal) in the presence of binding to non-target sites [100] . nAChRs, for example, comprise many subtypes expressed by at least 16 different genes [6, 103] .
Many of them share a high degree of sequence identity and similarity with other nAChRs and also with other ligand- gated ion channels [104] . Therefore, detailed investigation of non-target sites is important for the development of PET radiotracers for neuroimaging of nAChRs. In some cases, it is not the sequence-similarity of target proteins that is responsible for cross-reactivity but the chosen lead structure. A well-known example is vesamicol, which is the only known lead structure for targeting the vesicular acetylcholine transporter (VAChT). It has only a tenfold higher affinity for VAChT than for σ receptors in the brain [105] . Improving this selectivity is still a challenge in the development of PET radiotracers for the VAChT [106] .
The receptor densities and affi nities of the respective ligands in target tissues are parameters that can be quantified in vivo by molecular imaging with PET. They are important during radiotracer development. To obtain such information, in vitro radioligand-binding assays can be used [100, 101] . The total binding measured in these assays is always a sum of target-specific binding, which has limited capacity and is saturable, and non-specific binding, which has a high capacity and is non-saturable at pharmacologically meaningful concentrations [100] .
Given that the receptor density is determined by the target, higher BP values can only be achieved by higher ligand affi nity. The binding affi nity in vitro and in vivo may differ considerably because of the presence of different affi nity states and other confounding factors [107] . Therefore, in vitro binding assays are the methods of choice to experimentally determine the affinity of new ligands. In particular, homogenate-binding or cell-binding assays allow high-throughput screening if needed. Alternatively, autoradiography on brain slices may be used; this is much more time-consuming but allows additional investigation of the regional distribution of receptors in the brain [100, 108] .
With regard to nAChRs, the α4β2 subunit distribution has been investigated by in vitro autoradiography using [109, 110] while the α7 nAChR has been characterized using [
125 I]α-bungarotoxin [111, 112] or [ 3 H]methyllycaconitine [113] .
For various reasons, these three ligands are not suitable as lead compounds for PET radiotracer development [6] .
However, these highly selective compounds can be used to obtain information on the specifi c receptor binding of new drugs. For example, the highly-selective α7 nAChR ligand NS10743 [114] (for structure see Fig. 7 ) is able to displace the binding of [ 125 I]α-bungarotoxin in the mouse brain ( Fig. 3 ).
Concerning the α4β2 nAChR subtype, epibatidine has been used successfully as a lead compound since it has long been known for its high affinity for heteromeric nAChRs [115] . However, it has rather high toxicity arising from its potency and capacity to activate many different neuronal nAChR subtypes [116] .
In order to improve the subtype selectivity, the fl uorofor-chloro-substituted homoepibatidine analogue, fl ubatine (previously called NCFHEB), has been synthesized [117] ( affinities comparable to that of epibatidine and that the (+)-enantiomer has two-fold higher affinity than the other stereoisomer [117] .
As expected from previous studies with fluoro-and norchloro-analogues of epibatidine [116] , the newly-designed homoepibatidine analogues have 20-to 60-fold lower affinities to ganglionic α3β4 nAChRs than to the α4β2 subtype [117] . For fl ubatine, the increase in subtype selectivity seemingly results in decreased pharmacological sideeffects compared to epibatidine. Intraperitoneal injection of 25 μg/kg (+)-flubatine or (-)-flubatine into awake mice is without important pharmacological effects [118] . and 1.55 μg/kg for (+)-fl ubatine after i.v. injection [119] . These values are about ten-fold higher than those reported for N-methylepibatidine [120] and fl uoro-norchloroepibatidine [121] .
Regarding α7 nAChRs, many drug companies are developing receptor agonists and/or positive allosteric modulators for the treatment of schizophrenia and dementia [97] . Recently, NS10743, developed by NeuroSearch A/S (Ballerup, Denmark), has been characterized as a lead structure for PET radiotracer development. >10 μmol/L, respectively [114] . Together with autoradiographic evidence of specific receptor binding as shown in Fig. 3 , these data encouraged the radiolabeling of NS10743 to obtain an α7 nAChR-selective PET radiotracer [114] .
Occasionally, there is a lack of specific drugs that interact with certain brain proteins. For example, only a single lead compound AH5183, later called vesamicol [122, 123] , has been identified for the VAChT so far. Accordingly, all the PET radioligands that have been developed for neuroimaging the VAChT are derivatives of this lead structure [106] . Major drawbacks of vesamicol are the relatively low affi nity (K i >10 nmol/L) and lack of selectivity.
It binds to σ receptors with only ten-fold lower affinity [105] as well as to a "vesamicol-binding-protein" [124] . Similar affinity and selectivity have been found for (-)-FEOBV [125] , a radioligand first described in 1993 [126] and recently chosen for human VAChT studies [127] . Autoradiographic investigations of the human brain have revealed that region of patients with AD [128] . Although this was interpreted as cholinergic depletion, reduced σ 1 receptor binding cannot be excluded, because a 26% loss of this receptor has also been described in the CA1 region of patients with AD [90] . So far, no ideal PET radiotracer for the VAChT has been developed [106] and optimization of the binding affi nity of vesamicol-type ligands has been hampered by the lack of respective quantitative structure-activity relationships.
Therefore, molecular modeling approaches have been used to predict the binding affinity of vesamicol-type/like ligands for VAChT from their molecular structures [125, 129] .
A completely different situation is found with regard to radiotracer development for σ 1 receptor imaging. These receptors have an unusual multi-drug binding spectrum and the respective ligands cover diverse structural classes [89] . Therefore, selectivity not only for the other subtype (σ 2 receptor) but also for a great variety of further potential binding sites needs to be considered. Choosing spiropiperidines as lead structures, which fulfill these criteria and display a lack of signifi cant binding to a great variety of different targets [130] [131] [132] , has enabled successful PET radiotracer development [89] . However, structural modifi cation was needed to introduce fl uorine in a suitable labeling position. Accordingly, various series of derivatives have been synthetized to select those with the highest affinity, selectivity, and in vitro metabolic stability [133] [134] [135] [136] [137] [138] .
Very high selectivity towards the VAChT has been found, excluding cross-reactions with this target [139] .
Physicochemical Characterization of Lead Compounds
Besides affi nity and selectivity, some basic physicochemical properties of the parent compound have to be considered before radiolabeling. Lipophilicity, measured for example as logP and/or logD in octanol/water partition experiments, and molecular weight are important determinants for the compound´s ability to cross the BBB [140, 141] . Small-molecule drugs may sufficiently cross the BBB via lipid-mediated free diffusion if they have a molecular weight <400 g/mol and form <8 hydrogen bonds [141] . However, the majority of small-molecule drugs and all large-molecule drugs lack these chemical properties [141] . Considering these limitations, increasing lipophilicity may enhance the BBB permeability, but it also tends to increase plasma protein binding, causing a decrease of drug availability. Consequently, a parabolic relationship exists between lipophilicity and BBB permeability [107] . For a series of benzamides targeting the dopamine D 2 receptor, an optimal logP between 2 and 3 has been determined [142] . Accordingly, there is a rather small window of appropriate combinations of lipophilicity, molecular weight, and affi nity. Nevertheless, a nearly infi nite number of substances can theoretically be synthesized from basic organic elements within the restraints described above.
Significant deviations from the above parabolic relationship have been found, which can be ascribed to the existence of multiple mechanisms of drug transport through the BBB [143] . There is clear evidence that the expression of active efflux pumps like the multidrug transporter P-glycoprotein (P-gP) at the BBB accounts for the poor permeability of certain drugs (see below). Undoubtedly, P-gP is an important barrier to the entry of hydrophobic drugs into the brain [144] . Thus, proper prediction needs to consider active transport phenomena.
Furthermore, a variety of nutrient transporters expressed at the BBB are able to transport certain xenobiotics and drugs [141, 143] . Recently, it has been shown that the α4β2 [118] .
Preparation of Labeling Precursors and Radio labeling
Considering the short half-lives of the radionuclides used for radiolabeling (e.g., 20.4 min for 11 C and 109.8 min for 18 F) they need to be incorporated into appropriate precursor molecules quickly. Ideally, the precursor molecules should allow rapid labeling in a maximum of two synthetic steps.
As a rule of thumb, the whole labeling procedure including purifi cation and formulation of the fi nal product, should not last longer than two to three half-lives (for 11 C). Accordingly, labeling precursors are not necessarily chemically similar to the respective radiolabeled compound/non-radiolabeled reference compound.
Furthermore the precursor should allow (1) into organic molecules has been a particular challenge to synthetic chemists and has led to the development of specialized fl uorination techniques and reagents [145, 146] .
Generally, fluorine can be introduced into organic molecules by electrophilic fluorination reactions using elemental fluorine or by nucleophilic fluorination using inorganic and other ionic fluorides. [147] [148] [149] Unfortunately, the products suffer from low specifi c activity owing to the carrier-added non-radioactive fluorine [147, 148] and thus are excluded from use for neuroreceptor imaging.
The only exception is the post-target-produced highly specific [ 18 F]F 2 of up to 55 GBq/μmol [150] and its use for [ 18 F]CFT synthesis, a dopamine transporter ligand [151] .
Therefore, no further attention is given to electrophilic radiofluorination in this review. Furthermore, special methods for 18 F-labeling of peptides and proteins are not considered, because these molecules are not suitable for brain imaging due to their very low BBB transport rates [152] . [153, 154] .
In the presence of aprotic or very weakly-acidic protic For aliphatic nucleophilic substitutions [155] , in most cases, the anions of sulfonic acids such as trifl ate, tosylate, mesylate, or nosylate groups are the preferred leaving
groups. An option to introduce 18 F to aliphatic (or even deactivated aromatic) moieties of a molecule is the use of its halide derivatives. The approximate order of increasing suitability for aliphatic reactions is: I > Br > Cl > F, which is the reverse of that found in aromatic nucleophilic substitution reactions [156] . In the radiolabeling of various fl uoro-alkyl indiplon derivatives, the use of bromine as the leaving group has an RCY (38-43%) similar to the use of a tosylate leaving group [157] [158] [159] . Notably, depending on the length of the alkyl chain, O-tosyl-containing precursor molecules gradually decompose over months [159] . Using a halide leaving group, even isotopic 19 F (stable fl uorine) for 18 F exchange with minor precursor amounts is an option [160] .
Ring opening of cyclic reactive entities offers another method for the introduction of radiofl uorine [161] .
Fluoro-aromatic compounds are known to be extraordinarily stable. This is true for the C-F bond too. or nitro groups or special combinations of both act as leaving groups [162] . [163] . The original radiosynthesis using a bromo-pyridine precursor and an ethoxycarbonyl protecting group at the tropane nitrogen requires a microwave reaction followed by chiral HPLC separation of the enantiomers and provides overall RCYs of only 2%, which is insufficient for routine clinical PET investigation [164] . results with an RCY of 60 ± 5% [163] . The radiosynthesis was independent of the use of a microwave and was easily transferable to automated synthesis modules to prepare for human application. Recently, automated synthesis has been reported by two institutions with RCYs of 30% [165] and 25% [166] .
The above-mentioned electron withdrawing groups (-I effect, -M effect) bound to aromatic moieties are a definite need to enable a nucleophilic attack. In a recent study on radiolabeling of cannabinoid receptor type 2-selective compounds (Fig. 6) , the summarized effect of bromine in the meta-position to the leaving group -NO 2 was regarded to be not strong enough to achieve an RCY >3% [167] . An introduction of nitrogen into the aromatic ring facilitated the nucleophilic substitution (RCY >28%) but reduced the affinity by a factor of 30 [167] . To retain the affinity (K i = 4.3 nmol/L), a -N(Me 3 ) + precursor was synthesized and used for radiolabeling and provided RCYs between 30% and 35% [168] .
Besides low labeling yields, the use of bromine precursors may have further disadvantages such as an unsatisfactory quantitative separation of the radiolabeled product and its precursor (Fig. 7) . Initial attempts to use a bromine precursor for radiolabeling of NS10743, a highly selective α7 nAChR ligand, failed.
For some molecules, the structure does not allow nucleophilic substitution or the radiotracers decompose under the accompanying harsh conditions. In these cases, labeling can be achieved by a multistep procedure using small generic groups that allow both derivatisation with fl uorine as well as convenient introduction of radiofl uorine.
These groups are referred to as secondary labeling precursors or prosthetic groups [148, 169, 170] . A large number of these 18 F-labeled intermediates have been prepared
and investigated, such as amines, alcohols, aldehydes, ketones, carboxylic acids, esters, and halides [148] . interesting prosthetic groups as they can be coupled to a variety of molecules using the Huisgen "click" reaction which proceeds in high RCYs in aqueous solution under mild conditions. Thus, it can be used for the radiolabeling of water-soluble biomolecules [148, [171] [172] [173] [174] [175] . Generally, careful selection of prosthetic groups is critical for radiotracer development as they often exert great infl uence on target binding and/or in vivo stability [169] .
A further path to 18 We have recently used 18 F-labeled alkyltosylates for the radiolabeling of phenolic precursors via etherification to obtain high-affinity and selective radiotracers for the serotonin transporter [177] and the enzyme phosphodiesterase 10A [178] , respectively, with RCYs between 11% and 25%. High metabolic stability of the ether bond is expected because negligible defluorination was observed [178] . By contrast, [ 18 F]fl uoroacetamides have proven to be metabolically unstable due to hydrolytic cleavage [169] . Thus, high-affinity and selective radiotracers for the VAChT [179] and the GABA A receptor [180] , respectively, are not suitable for in vivo imaging because metabolites that cross the BBB are generated. The metabolic instability is caused by the action of hydrolytic enzymes, e.g. carboxylesterase [169] . In such cases, the use of [ 18 F]fluoropropane sulfonamides can be recommended because of their stability against carboxylesterase-mediated hydrolysis [169] .
Specifi c Binding of Radiotracers in vitro
To determine the specific target binding of newlydeveloped radiotracers, various in vitro binding assays can be used [100] . These provide specifi c features useful for target characterization and in vitro screening; an example of affinity determination of [ 18 F]NS10743 [114] is shown in radiotracer concentrations to obtain data on target density and radiotracer affinity. As expected, these clearly show the highest receptor densities in the thalamus, superior colliculus, and nucleus interpeduncularis [181] . Unexpectedly, In another experiment (Fig. 11) , additional information was obtained on the selectivity of (-)-[ 18 F]fl ubatine for α4β2 nAChRs. The radiotracer binding in pig brain was inhibited by co-incubation with various drugs of different selectivities for nAChRs. The nonselective inhibitor epibatidine [182] and the β2-subtype-selective inhibitors A-85380 [183] and cytisine [182] clearly reduced the (-)-[ 18 F]flubatine binding, whereas the α7-subtype-selective inhibitor MLA [184] did not. [185] derivative [186] is similar to that in rat brain (Fig.   12 ). Another example shows the use of [ 3 H]citalopram, the most selective serotonin transporter radioligand [187] , to obtain in vitro autoradiographs of serotonin transporter (SERT) distribution in the pig brain ( signifi cant correlation between the radioligands (r = 0.9, P < 0.001) was found [188] .
Usually, in vitro autoradiography is a good predictor of the imaging properties of a new radiotracer. However, radiotracers with unacceptable in vitro data are still able to provide good images in vivo. An example is the dopamine transporter-selective SPECT radiotracer [ 99m Tc]TRODAT-1.
In vitro autoradiography with this radiotracer shows a high non-specifi c background with less conspicuous binding in the rat striatum, a dopamine-transporter-rich brain region [189] .
Meanwhile, [ 99m Tc]TRODAT-1 has been introduced into the clinic as a tool for the diagnosis of Parkinson's disease [190] .
Metabolism of Radiotracers in Animals
Investigation of radiotracer metabolism in vivo needs special consideration, especially for neuroimaging.
Because of the exceptionally great functional diversity of the brain compared to other organs, there is a need to precisely differentiate between various brain regions with regard to specific radiotracer binding and target density.
Therefore, it has to be ensured that the PET image is derived from the radiotracer only and not blurred by the presence of radiolabeled metabolites. Consequently, the potential presence of radiometabolites in the brain needs to be investigated and ideally excluded. Furthermore, the use of compartmental models for the quantitation of receptor binding parameters depends on an exact measurement of the radiotracer availability for brain uptake. Accordingly, the radioactivity measured in blood samples needs to be corrected by subtraction of the amount of radiometabolites. A common concern in the development of PET radiotracers for neuroimaging is the presence of lipophilic metabolites in blood, because they are likely to cross the BBB just because of their lipophilicity [107] . Such metabolites may either be active, i.e. having a target-affinity high enough for significant binding, or inactive. In the former case, quantification is highly confounded because the measured signal represents undetermined proportions of parent tracer and metabolite, each of which may have a different affinity for the target [107] . In the latter case, non- specifi c binding is increased, leading to a decreased signalto-noise ratio. [191] . In the brain, it contributes to non-specifi c binding.
However, the signal obtained from specific receptor binding is regarded to be unchanged because the affi nity of altanserinol for serotonin receptors is negligible [191] . This offers the possibility of using [ 18 F]altanserin together with a constant infusion paradigm for quantification of 5-HT 2A
receptor availability in the brain [191, 192] . Alternatively, the use of the simplified reference tissue model (see below)
allows consideration of the presence of radiometabolites in brain, as long as their contribution to non-specifi c binding is homogenous throughout and there is a reference region without specifi c binding [193] . [194] , [ 11 C]β-CIT [195] , [196] , [ 11 C]PE2I [197] , and [ 11 C]/[ 18 F]LBT-999 [198] .
Confounding effects of brain metabolites on dopamine transporter (DAT) imaging have been observed for a variety of radiotracers such as [ 123 I]β-CIT
In the case of β-CIT, lipophilic metabolites have been detected [194, 195] . Accordingly, labeling of β-CIT with 11 nor-β-CIT entered and accumulated in the striatum and thalamus. Notably, nor-β-CIT has been found to specifi cally bind to the serotonin transporter [199] , providing an additional confounding effect.
Regarding [ 11 C]PE2I, a benzyl alcohol metabolite derived from biotransformation by cytochrome P450 enzymes residing predominantly in the liver [200] , has been shown to cross the BBB [197] . In the brain, it is supposed the DAT [198] .
For [ 18 F]FECNT, N-dealkylation has been shown
to provide a brain-penetrant radiometabolite of even higher in vitro DAT affinity than the parent compound itself, preventing the use of a reference tissue model for quantitation [196, 201] .
Lipophilicity is not necessarily a prerequisite for [202] [203] [204] , at least partly mediated by carboxylic acid transporters at the BBB [205] . [206] , or GABA A receptors [180] , preventing the use of these radiotracers for neuroimaging. Interestingly, it was found that fl uoroacetate is defluorinated by glutathione S-transferases [207] which are highly expressed in brain tissue [208] . To explain the high amounts of radioactivity in rat ventricles after injection of [209] is about twice as fast as measured in humans [210, 211] . Another very good example is the α4β2 nAChR PET radiotracer (-)-[ 18 F]flubatine. Rather strong differences between pigs and humans have been reported. While ~60% of metabolites were found in pig plasma at 2 h after injection [212] , this value was only ~10%-15% in humans [213] .
Because of this very low amount of radiolabeled metabolites, full kinetic modeling was possible even without metabolite correction of the input function [214] , which is of great advantage for routine clinical use.
The high metabolic stability of flubatine has recently been confi rmed in an in vitro study comparing mouse and human microsomal preparations (containing enriched cytochrome P450 enzymes [215, 216] ), where a 5-6-times faster metabolism was found in mice. Interestingly, the (-)-enantiomer is significantly less stable than the (+)-enantiomer (unpublished data). Stereoselective metabolism of drugs by P450 enzymes is a common phenomenon and may also explain differences in the metabolism of other enantiomeric PET radiotracers, such [211] or the σ 1 receptor-selective [136] .
Proof of Target-specifi c Binding in Animals
Usually one of the first steps to demonstrate target- Information on the time-dependent biodistribution of radiotracers can be obtained by ex vivo tissue sampling or small-animal imaging [7, 100] . The two methods are rather complementary than competitive, both offering advantages and disadvantages (see Table 2 ). More detailed information is available elsewhere [100] .
In addition to the use of rodents for ex vivo tissue sampling or small-animal imaging, larger animals such as monkeys or pigs are used for PET imaging with human scanners.
Independent of the type of in vivo study chosen, the strategy to obtain certain information about the radiotracer is similar. Studies have to show that the brain uptake is sufficiently high, specific, and selective to justify human application for neuroimaging. Furthermore, data obtained on whole-body radiotracer kinetics can also be used to estimate the absorbed radiation dose as a prerequisite for human application [217] .
The magnitude of brain uptake is mainly determined by the size, lipophilicity, and H-bonding capacity of the radiotracer [141, 218] , i.e. parameters accessible by in vitro investigations. The brain uptake may occasionally be confounded by affinity for efflux transporters at the BBB.
A variety of in vitro systems representing the BBB have been described, but the optimal use of these data, in terms of extrapolation to human unbound brain concentration profiles, remains to be fully exploited [219] . Therefore, animal experiments are still indispensable to investigate this aspect. Notably, the expression of the various efflux transporters at the BBB differs significantly between species [220, 221] . Among drug transporters, breast cancer resistance protein appears to be most abundant with an expression level ~2-fold greater in humans than in mice. By contrast, the expression level of P-gP in humans is ~2.5-fold lower than the corresponding mdr1a gene in mice [221] . Consequently, low brain uptake in rodents does not necessarily forecast the uptake in other species like humans. For example, the brain uptake of the high-affi nity and selective α7 nAChR ligand [ 18 F]NS14492 is ~10-times higher in pigs than in mice, suggesting suitability for human brain imaging [222] . Similar species differences between rats, guinea pigs, and monkeys have been reported for the [223] .
The specifi city and selectivity of brain uptake is another important issue to consider in animal experiments [7] . For [ 11 C]raclopride, in human and monkey [224, 225] . Since these early studies, the cerebellum has often been used as suitable reference region for the development of PET radiotracers for other dopamine receptors [226] , serotonin 5-HT 1A and 5-HT 2 receptors [227, 228] , muscarinic and nicotinic ACh receptors [229] [230] [231] , histamine receptors [232] , and the serotonin transporter [188, 233] . An example of ex vivo autoradiography of SERT distribution in rat brain where the radiotracer striatum, and substantia nigra [187, 234] clearly showed the highest radiotracer accumulation, providing evidence for radiotracer selectivity [188] . Furthermore, comparison with an in vitro autoradiograph of rat brain (Fig. 14A ) using the same radiotracer clearly showed a high correlation of SERT binding between the approaches.
An example of how an ex vivo binding ratio has been used to identify the radiotracer with the highest σ1 receptor binding in mouse brain among a series with various lengths of the alkyl side chain is shown in Fig. 15 . Notably, for the σ 1 receptor, as for metabotropic glutamate receptor 1 (mGluR1) [59] and the GABA A receptor [180] , the cerebellum is among the regions with the highest expression and cannot be used as a reference region in this case. The ratio between the region with lowest radiotracer accumulation (olfactory bulb) and that with highest accumulation (facial nucleus) was chosen for the estimation of specifi c receptor binding. Consistent with the highest brain-to-plasma ratio at 60 min post-injection and the highest target affi nity, this ratio was highest for the ethyl derivative [ 18 F]fl uspidine [89] .
Besides the use of reference regions for the evaluation of specific receptor binding in brain, blocking studies are recommended. A high concentration of a drug that binds specifi cally to the receptor site is injected before or together with the radiotracer and thereby prevents its specifi c binding to the target [100] . From the difference between a control study and the blocking study, information on the specific binding can be obtained. Using a similar setup, the target selectivity of the radiotracer can be investigated. As shown [235] ).
in Fig. 16 , the selectivity of the new SERT radiotracer norepinephrine uptake inhibitor, or GBR12909, a specific dopamine uptake inhibitor [235] . In contrast to the selective SERT inhibitor fl uoxetine, neither drug inhibited binding of In comparison to autoradiography, PET images of [236] .
Estimation of Receptor-binding Parameters in Animals
One of the great advantages of PET is the possibility of precise quantitation of local tracer concentrations in tissue;
this ultimately enables the estimation of receptor binding parameters in vivo. Preclinical PET studies in animals are suitable for this purpose [7, 8] and hence permit appropriate radiotracer evaluation. Initially, the PET scanner´s resolution was rather low (~10 mm) [238] allowing successful quantitation only in the brains of larger animals such as primates [239, 240] , dogs [241] [242] [243] , cats [244, 245] , and pigs [246] [247] [248] .
During the last decade, various dedicated PET cameras for imaging in small animals have been developed, providing a resolution of 1-2 mm [6, 249] .
Moreover, the first PET/MRI systems have become available for both human and small-animal imaging, allowing more accurate identification of brain regions [250] .
Thus, accurate quantitation is possible and similar to that achievable with autoradiography [7] . In addition, pharmacokinetic, multiple-tracer, and longitudinal studies can be performed in single subjects constituting a great potential for basic neuroscience research [251] , neuropharmacology [8, 252] , and the investigation of animal models of neurological and neuropsychiatric disorders [7] .
While in vitro autoradiography was the method of choice for receptor mapping for more than three decades, the suitability of animal PET/MRI for that purpose has recently been proven. For example, Syvänen [253] determined the GABA A receptor density, B max , in rat brain using four doses (between 4 μg and 400 μg) of reported, while K D remained unchanged [253] .
Although convincing in animals, a similar protocol applied to humans has major drawbacks. Multiple The BP can be estimated by compartmental modeling [254] [255] [256] [257] [258] [259] . For the evaluation of PET data, however, this is not a feasible strategy. It rather turns out that very simple oneor two-tissue compartmental models suffi ce to adequately describe the data at the given limits of spatial and temporal resolution. For a more in-depth description of the basics of compartmental modeling we refer the reader to the literature [258, 259] .
Typical examples of compartmental models are shown in Fig. 18 , where C a refers to the arterial plasma and BP estimated from these curves [209, 260] . This clearly demonstrated the specifi city of the radiotracer uptake. The selectivity for the norepinephrine transporter (NET) was demonstrated by pre-injection of maprotilin, a selective NET inhibitor [209] .
Accurate measurement of the arterial plasma timeactivity curve as well as consideration and correct determination of metabolites in plasma is important for receptor quantitation based on compartmental models using an arterial input function. This poses substantial problems in imaging of small animals and humans.
Therefore, alternative quantification strategies, called "references tissue models'' have been developed [261, 262] .
These models rest on the observation that (apart from underestimation of specifi c binding in the target region [257] .
PET also allows the visualization of specifi c receptor binding by estimation of the binding parameters in each voxel, i.e. each image point in the three-dimensional rectangular grid [263] . The higher the number of voxels, the higher the number of calculations to be executed.
To be able to perform about a million estimations in a analysis [264] [265] [266] and for those with reversible binding the Logan graphical analysis [267] have become the methods of choice. For the two-tissue compartmental model, the slope of the regression line in the Logan plot represents the total distribution volume V T , defi ned by K 1 /k 2 (1+k 3 /k 4 ) + fbv (fbv = fractional blood volume in the target region, k 3 /k 4 = BP [267] ). juvenile pig [230] . Newer developments include proposals to obtain parametric images even in cases without either an arterial input function or a reference region [268] , direct reconstruction algorithms of linear and nonlinear parametric images, and joint estimation of parametric images and input function [263] . Further validation of these concepts is still needed.
Proof-of-Concept in Humans
The final step in PET radiotracer development is proofof-concept in humans. A prerequisite to get permission for such studies is the transition of the biomarker from research-grade radiochemical to a radiopharmaceutical, for which higher standards of product quality must be met [269] . Many aspects of radiation safety, toxicology issues, quality control, licensing, and regulatory control need to be considered for the production of radiopharmaceuticals and these have been extensively reviewed elsewhere [5, 100, 270, 271] .
The regulatory framework has become increasingly restrictive during the last two decades. Therefore, the time between fi rst successful radiosynthesis of a new PET radiotracer and its first human use is at least between 5
and 10 years. For example, in the case of the α4β2 nAChR radiotracer (-)-[ 18 F]flubatine, the time between the first report on radiosynthesis [164] and the fi rst report on human use [16] [210, 272] , and for [ 18 F]FEOBV [126] , a radiotracer for the VAChT, it has been almost 20 years [273] . At the beginning of neuroreceptor imaging with PET this transition time was much shorter, in the range of 1-2 years as exemplifi ed by [ 11 C]raclopride [225, 274] , 3-N-[ 11 C]methylspiperone [224] , and [ 11 C]fl umazenil [49, 275] .
However, even if a radiotracer is not further developed into a radiopharmaceutical for imaging in human subjects it may fi nd widespread use in preclinical studies with special animal PET devices [276] to investigate animal models of diseases [7] or new drugs [8, 252] . 
Conclusion
The main focus of this review is the development and evaluation of radiolabeled ligands (radiotracers) in order to investigate brain functions in living organisms.
Application of radiotracers provides images of transport, metabolic, and neurotransmission processes on the molecular level. PET is a method used in humans to acquire such information. It is the most sensitive and specific molecular in vivo imaging method available at present. Through the integration of chemical/radiochemical, pharmaceutical/radiopharmaceutical, biochemical and radiopharmacological basic research, computational chemistry, and with the aid of nuclear medicine diagnostics, a new approach in neuroscience has been made available.
The foremost importance of this approach is the diagnosis and therapeutic monitoring of brain diseases.
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